Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 170

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Duration of Adjuvant Chemotherapy for Colon Cancer and Survival Among the Elderly

Open access
Neugut, Alfred I., Matasar, Matthew, Wang, Xiaoyan, McBride, Russell, Jacobson, Judith S., Tsai, Wei-Yann, Grann, Victor R., Hershman, Dawn L.·2006·Journal of Clinical Oncology

Abstract

Purpose: In randomized trials, patients with stage III colon cancer who received 6 months of fluorouracil (FU)-based adjuvant chemotherapy had better survival than patients who did not. However, little is known about the predictors of, or the survival associated with, duration of chemotherapy in the community. Patients and Methods: The linked Surveillance, Epidemiology, and End Results-Medicare database was used to identify individuals ≥ 65 years of age diagnosed with stage III colon cancer between 1995 and 1999. We used logistic and Cox proportional hazards regression models to analyze factors associated with early discontinuation of FU-based chemotherapy among these elderly colon cancer patients. Results: Among 1,722 patients who received 1 to 7 months of FU-based chemotherapy, older age, being unmarried, and having comorbid conditions were associated with receiving less than 5 months of treatment. Among the 1,579 patients who survived ≥ 8 months, the 1,091 (69.1%) who received 5 to 7 months of treatment had lower overall (hazard ratio [HR], 0.59; 95%, CI 0.49 to 0.71) and colon cancer-specific (HR, 0.53; 95% CI, 0.43 to 0.66) mortality than the 488 (30.9%) who received 1 to 4 months of treatment. Conclusion: More than 30% of elderly patients who initiated FU-based chemotherapy for stage III colon cancer and survived for at least 8 months discontinued treatment early. Mortality rates among such patients were nearly twice as high as among patients who completed 5 to 7 months of treatment. If the association we observed between duration of treatment and survival is confirmed, additional investigation is warranted to determine whether dose-intensity, cumulative dose, or other factors related to receipt of full adjuvant treatment are responsible.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.04.5005

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 170

Metadata

Authors
Neugut, A. I., Matasar, M., Wang, X., McBride, R., Jacobson, J. S., Tsai, W.-Y., Grann, V. R., & Hershman, D. L.
Venue
Journal of Clinical Oncology
Published
2006-05-20
Volume
24
Issue
15
Pages
2368-2375
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2140033791
Cited by
170
References
4
FWCI
6.36
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Duration of Adjuvant Chemotherapy for Colon Cancer and Survival Among the Elderly. https://app.cochat.ai/papers/10.1200/jco.2005.04.5005
The paper
Neugut, A. I., Matasar, M., Wang, X., McBride, R., Jacobson, J. S., Tsai, W.-Y., Grann, V. R., & Hershman, D. L. (2006). Duration of Adjuvant Chemotherapy for Colon Cancer and Survival Among the Elderly. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.04.5005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.